Johnson & Johnson (NYSE:JNJ) Shares Sold by Guardian Investment Management

Guardian Investment Management reduced its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 0.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 29,468 shares of the company’s stock after selling 75 shares during the quarter. Johnson & Johnson accounts for about 3.4% of Guardian Investment Management’s holdings, making the stock its 6th biggest position. Guardian Investment Management’s holdings in Johnson & Johnson were worth $4,298,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Financial Advantage Inc. purchased a new position in shares of Johnson & Johnson in the third quarter valued at $28,000. Kessler Investment Group LLC purchased a new position in shares of Johnson & Johnson in the fourth quarter valued at $29,000. Eii Capital Management Inc. purchased a new position in shares of Johnson & Johnson in the third quarter valued at $39,000. Permanens Capital L.P. boosted its stake in Johnson & Johnson by 33.3% during the third quarter. Permanens Capital L.P. now owns 400 shares of the company’s stock worth $52,000 after buying an additional 100 shares during the period. Finally, Candriam Luxembourg S.C.A. boosted its stake in Johnson & Johnson by 1.0% during the third quarter. Candriam Luxembourg S.C.A. now owns 416,526 shares of the company’s stock worth $58,000 after buying an additional 3,994 shares during the period. 67.28% of the stock is currently owned by institutional investors.

JNJ has been the subject of several recent analyst reports. Morgan Stanley raised shares of Johnson & Johnson from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $145.00 to $170.00 in a research note on Tuesday, December 17th. Zacks Investment Research upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $158.00 target price for the company in a report on Wednesday, December 18th. Atlantic Securities upgraded shares of Johnson & Johnson from an “underweight” rating to a “neutral” rating in a report on Wednesday, October 16th. Barclays upgraded shares of Johnson & Johnson from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $140.00 to $173.00 in a report on Thursday, December 19th. Finally, Wells Fargo & Co boosted their target price on shares of Johnson & Johnson from $155.00 to $165.00 and gave the stock an “overweight” rating in a report on Thursday, January 9th. Three equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Johnson & Johnson has an average rating of “Buy” and a consensus price target of $159.33.

In other news, Director Hubert Joly bought 5,000 shares of the company’s stock in a transaction that occurred on Friday, December 13th. The shares were purchased at an average price of $141.28 per share, for a total transaction of $706,400.00. Following the completion of the transaction, the director now directly owns 5,000 shares in the company, valued at $706,400. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Kathryn E. Wengel sold 2,017 shares of the company’s stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $141.07, for a total value of $284,538.19. Following the completion of the sale, the executive vice president now owns 51,736 shares in the company, valued at approximately $7,298,397.52. The disclosure for this sale can be found here. 0.23% of the stock is currently owned by insiders.

Shares of JNJ stock opened at $147.01 on Thursday. Johnson & Johnson has a fifty-two week low of $125.00 and a fifty-two week high of $147.84. The firm has a market capitalization of $385.62 billion, a price-to-earnings ratio of 16.71, a PEG ratio of 2.36 and a beta of 0.71. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.00 and a current ratio of 1.26. The stock’s 50-day simple moving average is $143.07 and its 200-day simple moving average is $134.77.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, October 15th. The company reported $2.12 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.00 by $0.12. Johnson & Johnson had a return on equity of 39.81% and a net margin of 21.09%. The business had revenue of $20.73 billion for the quarter, compared to analyst estimates of $20.14 billion. During the same quarter in the previous year, the firm earned $2.05 earnings per share. The company’s revenue was up 1.9% on a year-over-year basis. As a group, equities analysts forecast that Johnson & Johnson will post 8.66 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 25th will be paid a dividend of $0.95 per share. The ex-dividend date of this dividend is Monday, February 24th. This represents a $3.80 dividend on an annualized basis and a dividend yield of 2.58%. Johnson & Johnson’s payout ratio is 46.45%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

See Also: Beige Book

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.